<DOC>
	<DOCNO>NCT00347009</DOCNO>
	<brief_summary>This 36-month open-label study adefovir dipivoxil investigate clinical benefit therapy chronic hepatitis B patient advance fibrosis cirrhosis confirm biopsy . Primary endpoint histological improvement define decrease Ishak Fibrosis Score one point baseline Month 36 adefovir dipivoxil treatment . Approximately 150 patient recruit study centre Asia Pacific area . The patient offer 36 month open label adefovir dipivoxil treatment , assessment every three month , 6-month post study treatment follow-up prior study completion . After 36 month study treatment , likely patient benefit continue treatment adefovir dipivoxil . If case investigator clinical judgement , investigator ensure routine prescription available timely manner , unnecessary interruption treatment occur .</brief_summary>
	<brief_title>Adefovir Dipivoxil For The Treatment Of Patients With Chronic Hepatitis B Related Advanced Fibrosis Or Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<criteria>Male female patient ≥ 18 year age A female eligible enter participate study : ) nonchildbearing potential ( ie . Physiologically incapable become pregnant , include female premenarchal postmenopausal ) ; b ) childbearing potential negative serum pregnancy test screen , agree one following : complete abstinence intercourse 2 week prior administration study drug , throughout study , time interval completion premature discontinuation study account elimination investigational drug , ( minimum 5 halflives longer pharmacodynamic profile investigational drug warrant long time period ) ; , Female sterilization ; Sterilization male partner ; Implants levonorgestrel ; , Injectable progestogen ; Oral contraceptive ( combine progestogen ) ; , Any intrauterine device ( IUD ) publish data show low expected failure rate le 1 % per year ( IUDs meet criterion ) ; , Any method publish data show low expected failure rate method le 1 % per year ; , Barrier method use combination acceptable method . Documented chronic hepatitis B infection determine presence serum HBsAg least 6 month ( positive least 6 month screen time screen visit . ) Positive HBV DNA plasma assay screen value ≥ 1 x 10^5 copy /mL . ( Roche COBAS AMPLICOR TM HBV Monitor Test , LLOD &lt; 300 copies/mL ) Adequate renal function define serum creatinine ≤1.5 mg/dL ( ≤130 µmol/L ) . Willing able undergo two liver biopsy ( prior dosing , 36 month therapy ) . The study baseline liver biopsy recent liver biopsy take within 6 month enrollment , long biopsy take 6 month completion interferon 3 month completion antiviral treatment ( eg . famciclovir , lamivudine etc . ) , patient interferon therapy antiviral therapy biopsy screening . Liver biopsy show advance fibrosis/cirrhosis ( Ishak fibrosis score ≥4 ) . The slide must available review independent histopathologist . Availability willingness subject provide write informed consent per ICH/GCP local Guidelines . 1 . ALT &gt; 10XULN screen 2 . ChildPugh Score ≥ 7 3 . History acute exacerbation lead transient decompensation 4 . Coinfections HIV , HCV HDV . Note : Patients antiHCV seropositive HCV RNA undetectable consider HCV seropositive eligible enrollment . 5 . Any following laboratory parameter within 4 week prior study entry : Haemoglobin &lt; 8.0 g/dL , Absolute neutrophil count ( ANC ) &lt; 1.5 x 10^9/L , Platelet count ≤50 x 10^9/L , Pancreatic amylase and/or lipase &gt; 2 x ULN Screening alphafetoprotein ( AFP ) value &gt; 50 ng/mL Clinical , ultrasonographic radiologic evidence hepatic mass suggestive hepatocellular carcinoma . Significant concurrent medical and/or psychiatric condition hepatitis B opinion investigator might interfere patient 's treatment , assessment compliance accord study requirement , malignancy , congestive heart failure , renal failure , chronic pancreatitis , diabetes mellitus poor control alcoholism . Any following medication 2 month prior study entry ( expectation subject receive course study ) : Nephrotoxic medication ( eg aminoglycosides , amphotericin B , vancomycin , cidofovir , foscarnet , cisplatin , pentamidine ) competitor renal excretion ( eg probenecid , sulfinpyrazone ) , Hepatotoxic medication ( eg anabolic steroid , ketoconazole , itraconazole , isoniazid , rifampin , rifabutin ) . Treatment immunosuppressive/immunomodulatory agent ( include interferon corticosteroid ) within 6 month prior study entry . Presence cause liver disease ( ie . hemochromatosis , Wilson 's disease , alcoholic liver disease , nonalcoholic steatohepatitis , autoimmune hepatitis , alpha1 antitrypsin deficiency ) . A history liver transplantation /planned liver transplantation . Pregnancy ( lactation ) , subject capable bearing child , inability/unwillingness practice adequate contraception . Females childbearing potential ( postpuberty ) willing unable pregnancy test study visit . History hypersensitivity nucleoside and/or nucleotide analogue . Concurrent participation another clinical trial subject expose another investigational noninvestigational drug device within 30 day screen visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Cirrhosis</keyword>
	<keyword>Advanced Fibrosis</keyword>
	<keyword>Chronic Hepatitis B</keyword>
	<keyword>Adefovir Dipivoxil</keyword>
</DOC>